Contraceptive Technology Update – October 1, 2007
October 1, 2007
View Issues
-
New data released underscores safety of dedicated continuous-use pill
New research released on Lybrel, the first dedicated continuous use oral contraceptive (OC) (Wyeth Pharmaceuticals; Collegeville, PA), underscores the safety of the new drug. -
Use counseling tips for continuous-use pill
Your next patient says she is interested in using Lybrel, the new continuous-use oral contraceptive (OC). What should you tell her about this form of birth control? -
New microbicide for HIV prevention now in trials
Researchers have launched a clinical safety trial of VivaGel (SPL7013), a topical vaginal microbicide, for potential use in preventing the sexual transmission of HIV. -
New review boosts knowledge of implants
Your next patient is a young mother of three who is looking for long-term, effective contraception. She says she is not ready to consider tubal sterilization. What methods can you offer her? -
Uninsured women are not getting Pap smears
How many women in your family planning facility may be missing a needed Pap smear? Check your numbers: One-fourth of uninsured U.S. women between the ages of 18-64 report not having had a Pap smear within the last three years of a government-issued survey. -
STD Quarterly: New research indicates circumcision does not affect women's STD risk
With findings suggesting that male circumcision reduces risk of HIV acquisition for men, researchers now are turning attention on circumcision's impact on acquisition of sexually transmitted disease (STD) for women. -
STD Quarterly: Older women may not know their risk for HIV
If your practice includes older women, what is your approach in discussing risks for HIV? It's time to address such issues. Results of a new study indicate that older women may not be interested in being tested for HIV, despite having significant risk factors for lifetime exposure.